Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States.

ABSTRACT:

Background

Many patients do not reach recommended low-density lipoprotein cholesterol (LDL-C) levels on statins alone. Inclisiran is a small interfering RNA providing ∼50% further reduction in LDL-C.

Objectives

The authors estimated the number of U.S. adults eligible for inclisiran and the number of preventable atherosclerotic cardiovascular disease (ASCVD) events with inclisiran use.

Methods

Using a cross-sectional study of the National Health and Nutrition Examination Survey 2011 to 2020, the authors identified 3 cohorts: high-risk primary prevention (≥20% 10-year ASCVD risk or 7.5% to <20% with ≥2 risk-enhancing factors), diabetes, and secondary prevention. Included adults were ≥18 years with LDL-C ≥70 mg/dL (≥55 mg/dL if very high-risk for ASCVD events) despite st

SUBMITTER: Wong ND 

PROVIDER: S-EPMC12859191 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature